Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeronMIL:1GERN 20 Debt-to-Equity is 0.56 as of Jun. 2026, which is 107% above its 10-year median of 0.27. GuruFocus rates MIL:1GERN with a GF Score™ of 20/100 and a GF Value™ of €6.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Geron ranks worse than 77.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Geron's Debt-to-Equity or its related term are showing as below:
MIL:1GERN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.27 Max: 0.7
Current: 0.56
During the past 13 years, the highest Debt-to-Equity Ratio of Geron was 0.70. The lowest was 0.00. And the median was 0.27.
MIL:1GERN's Debt-to-Equity is ranked worse than 77.89% of 959
companies
in the Biotechnology industry
Industry Median: 0.15
vs MIL:1GERN: 0.56
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Geron Debt-to-Equity Related Terms
Geron Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Geron's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1GERN vs PHAT, KURA, ODTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Geron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Geron's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (MIL:1GERN) has a Debt-to-Equity of 0.56 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Geron and its competitors. This is 107% above median its historical median of 0.27. According to the industry distribution chart, Geron ranks #747 out of 959 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Geron's Debt-to-Equity too high?
Geron's current Debt-to-Equity of 0.56 is 107% above median its 10-year median of 0.27. The Biotechnology industry median Debt-to-Equity is 0.15. Geron's value of 0.56 is 273.3% above this industry median. Based on the distribution chart, Geron ranks #747 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Geron has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Debt-to-Equity compare to PHAT and KURA?
According to the Biotechnology industry distribution chart, Geron ranks #747 out of 959 companies for Debt-to-Equity. This places Geron in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Geron's value of 0.56 is 273.3% above this benchmark. While the company's 10-year median is 0.27 vs. the industry median of 0.15, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current Debt-to-Equity of 0.56 is 273.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Geron and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Debt-to-Equity is 0.56, which is 107% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (MIL:1GERN) is currently considered Possible Value Trap. The stock's GF Value™ is €6.00, compared to a current price of €1.30 — trading 78.4% below its estimated fair value. The current Debt-to-Equity is 0.56, which is 107% above median its 10-year median of 0.27 and 273.3% above the Biotechnology industry median of 0.15. Geron's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Geron (MIL:1GERN), the current Debt-to-Equity is 0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (MIL:1GERN) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.30 is trading 78.4% below its estimated GF Value™ of €6.00.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for MIL:1GERN:
Debt-to-Equity: 0.56 (107% above median its 10-year median of 0.27)
GF Value™: €6.00 vs. price of €1.30 (78.4% below fair value)
Industry Position: 273.3% above the Biotechnology median (#747 of 959)
No single metric tells the full story. See the MIL:1GERN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
20GF Score
Get the complete analysis for MIL:1GERN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1GERN has been successfully added to your 
